rs113001196
Variant summary
The NM_000138.5(FBN1):c.6658C>T (p.Arg2220Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant is predicted to lead to nonsense-mediated mRNA decay (NMD). The variant allele was found at a cumulative frequency of 0.000000684 (AC=1) in the gnomAD database across 1,461,324 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000009. In-silico predictor (BayesDel (noAF)) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 10.00). Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★).
Frequency
Consequence
NM_000138.5 stop_gained
Predictors
Clinical Significance
Conservation
Publications
- familial thoracic aortic aneurysm and aortic dissectionInheritance: AD, Unknown Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- Marfan syndromeInheritance: AD, AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, G2P, Ambry Genetics, Labcorp Genetics (formerly Invitae), Orphanet
- Acromicric dysplasiaInheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- progeroid and marfanoid aspect-lipodystrophy syndromeInheritance: AD Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet, Labcorp Genetics (formerly Invitae)
- stiff skin syndromeInheritance: AD Classification: STRONG, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Weill-Marchesani syndrome 2, dominantInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- geleophysic dysplasiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- isolated ectopia lentisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- neonatal Marfan syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Weill-Marchesani syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- ectopia lentis 1, isolated, autosomal dominantInheritance: AD Classification: LIMITED Submitted by: G2P
- Shprintzen-Goldberg syndromeInheritance: AD, Unknown Classification: LIMITED, NO_KNOWN Submitted by: ClinGen, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
Classification according to ACMG Germline Pathogenicity v2019
Our verdict: Pathogenic. The variant received 16 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| PVS1Null variant in LOF gene | Frameshift/stop-gained, NMD predicted, LoF disease mechanism — very strong (PVS1); Stop-gained (exon 55 of 66) at amino acid 2220 of 2871, predicted to trigger nonsense-mediated mRNA decay. Loss of function is a known disease mechanism for this gene. | ||
| PS2Confirmed de novo variant | ClinVar submission reports a confirmed de novo occurrence (PS2_Supporting); SCV000829945: In at least one individual the variant was observed to be de novo.; SCV002767685: Subsequent analysis of parental samples indicated this variant to be de novo.; SCV000787253: affected individual with de novo origin (ClinVar observation); SCV004045939: affected individual with de novo origin (ClinVar observation) | ||
| PS4Prevalence increased in affected individuals | Rare variant reported in affected individuals by ≥2 independent ClinVar submitters (PS4_Supporting); 7 ClinVar submitter(s) report the variant in affected individuals; SCV000058896: The Arg2220X variant (FBN1) has been reported in two Japanese probands with clin ical features of Marfan syndrome and was absent in 100 control chromosomes from healthy Japanese individuals (Matsukawa 2001, Ogawa 2011). In addition, this var iant has been identified in 1/1090 chromosomes from a broad, though clinically a nd racially unspecified population (dbSNP rs113001196).; SCV000233877: Identified in a patient with isolated TAAD (iTAAD) in published literature (PMID: 33824467); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 39843441, 34916231, 36517271, 25525159, 21907952, 17657824, 12938084, 23684891, 22772377, 27112580, 29357934, 26787436, 35058154, 33824467, 11139245); SCV000741017: This alteration has been reported in cohorts of subjects with FBN1-related disease (Matsukawa R et al. Hum Mutat, 2001;17:71-2; Comeglio P et al. Hum Mutat, 2007 Sep;28:928; Somers AE et al. Am J Med Genet A, 2016 Jul;170:1786-90; Becerra-Muñoz VM et al. Orphanet J Rare Dis, 2018 Jan;13:16; Meester JAN et al. Genet Med, 2022 May;24:1045-1053).; SCV000829945: This premature translational stop signal has been observed in individual(s) with Marfan syndrome (PMID: 11139245, 17657824, 22772377, 23684891, 27112580, 29357934).; SCV000885419: The FBN1 c.6658C>T; p.Arg2220Ter variant (rs113001196) has been described in several individuals affected with Marfan syndrome (Attanasio 2013, Collod-Beroud 2003, Comeglio 2007, Matsukawa 2001, Ogawa 2011, Wang 2013).; (+2 more) | ||
| PM2Absent/extremely low in population databases | Very rare in gnomAD for AD/XL gene (popmax AF < threshold/10) — PM2; GnomAD popmax AF = 0.0000009 — very rare for AD+AR gene (threshold 0.0001) — PM2 moderate | ||
| PP5Reputable source reports pathogenic | ClinVar 2-star pathogenic — strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 2 star(s). ClinVar submissions strongly and reliably favor pathogenicity (14/14 total P/LP) |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_000138.5. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
FBN1 | MANE Select | c.6658C>T p.Arg2220Ter | stop_gained | Exon 55 of 66 | Prot: NP_000129.3 | |
FBN1 | c.6658C>T p.Arg2220Ter | stop_gained | Exon 54 of 65 | Prot: NP_001393645.1 |
Ensembl Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
FBN1 | MANE Select | c.6658C>T p.Arg2220Ter | stop_gained | Exon 55 of 66 | Prot: ENSP00000325527 | |
FBN1 | c.6658C>T p.Arg2220Ter | stop_gained | Exon 55 of 66 | Prot: ENSP00000806984 | ||
FBN1 | c.6658C>T p.Arg2220Ter | stop_gainedNMD_transcript | Exon 55 of 67 | Prot: ENSP00000453958 |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 4 sources | |||||
GnomAD3 genomes | Cov:32 | ||||
GnomAD4 exome | AF: 6.84e-7 | AC:1 | Hom:0 | AN:1461324 | Cov:32 |
GnomAD4 genome | Cov:32 | ||||
ALFA (dbGaP/dbSNP Allele Frequency Aggregator) | AF: 0.00 | AC:0 | Hom:0 | AN:187138 | |
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 37 | |
BayesDel_addAF | Pathogenic | 0.63 | D |
BayesDel_noAF | Pathogenic | 0.58 | |
CADD | Pathogenic | 46 | |
DANN | Uncertain | 1.0 | |
Eigen | Pathogenic | 0.96 | |
Eigen_PC | Pathogenic | 0.85 | |
FATHMM_MKL | Uncertain | 0.93 | D |
GPN-Star LLR | N/A | -11 | |
GPN-Star score | N/A | 11 | |
Mutation Taster | N/A | 1/199 | disease causing (ClinVar) |
PhyloP100 | Pathogenic | 10 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Benign | 0.090 | |
SpliceAI score (max) | Benign | 0.020 | Details are displayed if max score is > 0.2 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.